A small molecule inhibitor of Bcl-2, HA14-1, also inhibits ceramide glucosyltransferase.

Satomi Niino, Yutaka Nakamura, Yoshio Hirabayashi, Michiyo Nagano-Ito, Shinichi Ichikawa

Laboratory for Animal Cell Engineering, Niigata University of Pharmacy and Applied Life Sciences (NUPALS), 265-1 Higashijima, Akiha-ku, Niigata-shi, Niigata 956-8603, Japan.

Biochemical and biophysical research communications 2013 Apr 5

filter terms:

HA14-1 is a Bcl-2 inhibitor that is widely used for studies of apoptosis. In the course of searching for a ceramide glucosyltransferase inhibitor that catalyzes the first glycosylation step of glycosphingolipid synthesis, we unexpectedly found that HA-14-1 also has the ability to inhibit ceramide glucosyltransferase. The IC50 value of HA14-1 against ceramide glucosyltransferase is 4.5μM, which is lower than that reported for Bcl-2 in vitro. Kinetic analyses revealed that HA14-1 is a competitive and mixed-type inhibitor with respect to C6-NBD-ceramide and UDP-glucose, respectively. Copyright © 2013 Elsevier Inc. All rights reserved.

Citation

Satomi Niino, Yutaka Nakamura, Yoshio Hirabayashi, Michiyo Nagano-Ito, Shinichi Ichikawa. A small molecule inhibitor of Bcl-2, HA14-1, also inhibits ceramide glucosyltransferase. Biochemical and biophysical research communications. 2013 Apr 5;433(2):170-4